GT Biopharma (GTBP) Payables (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Payables of $253000.0 for Q1 2026, down 89.37% year-over-year from $2.4 million in Q1 2025, and down 66.18% quarter-over-quarter from $748000.0 in Q4 2025.
GT Biopharma (GTBP) Payables (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Payables for 17 consecutive years, with $253000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 89.37% year-over-year to $253000.0; the TTM figure through Mar 2026 stood at $253000.0 (down 89.37% YoY), while the FY2025 annual figure was $748000.0, down 80.59% from the prior year.
- Payables declined to $253000.0 in Q1 2026 per GTBP's latest filing, from $748000.0 in the prior quarter.
- Across five years, Payables topped out at $8.2 million in Q1 2022 and bottomed at $253000.0 in Q1 2026.
- Historically, Payables has averaged $3.0 million across 5 years, with a median of $2.5 million in 2024.
- Annual changes were most pronounced in 2023 — Payables soared 437.21% — and 2026, when it plunged 89.37%.
- GT Biopharma's Payables stood at $3.2 million in 2022, then jumped by 70.31% to $5.4 million in 2023, then dropped by 28.38% to $3.9 million in 2024, then tumbled by 80.59% to $748000.0 in 2025, then sank by 66.18% to $253000.0 in 2026.
- Business Quant data shows GTBP's Payables at $253000.0 in Q1 2026, $748000.0 in Q4 2025, and $913000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | 253,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 253,000.00 |
| Dec 31, 2025 | 748,000.00 |
| Sep 30, 2025 | 913,000.00 |
| Jun 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 3.85 Mn |
| Sep 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 1.62 Mn |
| Dec 31, 2023 | 5.38 Mn |
| Sep 30, 2023 | 2.17 Mn |
| Jun 30, 2023 | 5.04 Mn |
| Mar 31, 2023 | 6.06 Mn |
| Dec 31, 2022 | 3.16 Mn |
| Sep 30, 2022 | 3.38 Mn |
| Jun 30, 2022 | 938,000.00 |
| Mar 31, 2022 | 8.23 Mn |
| Dec 31, 2021 | 8.33 Mn |
| Sep 30, 2021 | 3.14 Mn |
| Jun 30, 2021 | 2.34 Mn |
| Mar 31, 2021 | 2.74 Mn |